Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Harlow, K. Oates, R. MacKenzie-Ross, J. Pepka-Zaba (Cambridge, United Kingdom). Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients. Eur Respir J 2012; 40: Suppl. 56, 1495

Member's Comments

No comment yet.

Related content which might interest you: Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001 Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1386-1395 Year: 2016 Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders Source: Eur Respir J 2002; 19: 664-671 Year: 2002 Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Reduced pulmonary capillary volume (Vc) is responsable for the increased alveolar exhaled nitric oxide (CANO) in patients with progressive systemic sclerosis (PSS) and pulmonary hypertension (PH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Long-term outcomes of pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 603s Year: 2007 Novel hypoxia system to assess endothelial dysfunction in chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral vs. central airways Source: Eur Respir J 2003; 22: Suppl. 45, 279s Year: 2003 Can fractional exhaled nitric oxide be useful to differentiate asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) from COPD-only Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020